Skip to main content
. 2015 Apr 22;194(11):5497–5508. doi: 10.4049/jimmunol.1401218

FIGURE 2.

FIGURE 2.

Production and integrity of WT hIgG1 and Fc-engineered variants. (A) Total amounts of anti-NIP hIgG1 variants produced from transient transfection of HEK293E cells. (B) Nonreducing SDS-PAGE of WT hIgG1 and Fc-engineered variants. (C) Binding of titrated amounts (1000.0–0.5 ng/ml) of anti-NIP WT hIgG1 and Fc-engineered variants to NIP-conjugated BSA. (D) A DSF thermal stability histogram showing the tm values for WT hIgG1 and Fc-engineered variants. Data are presented as mean ± SEM of experiments performed in triplicate (n = 3).